Trophogen, Inc. operates as a biotechnology company offering services organized around development of growth factors for therapeutic applications. These include affinity glycoprotein hormone and related growth factor analogs, enabling patients to treat ovarian, breast, prostate, testicular and thyroid cancers as well as human and animal infertility. Early funed by Marylamd basedToucon Capital, the firm is also involved in the research on proteins therapeutics; and drug development, including cystine-knot growth factor analogs.
